A call to action on antimicrobial stewardship in tuberculosis: safeguarding effective tuberculosis treatment for future generations Authors: Thomas Theo Brehm, Askar Yedilbayev, Ihor Perehinets, Diane Ashiru-Oredope, Dumitru Chesov, Christoph Lange, Onno W. Akkerman, Onno W. Akkerman, Anne M. Akkerman-Nijland, Aabid Ali, Muhammad Hasnain Ali, Alina Malic, Aysel Elman Aslanova, Filiz Duyar Ağca, Aylin Babalik, Yazeed Garba Bala, Ariful Basher, Adrian Belîi, Luisa Berckenhagen, Mathieu S. Bolhuis, Dragoş Băiceanu, Andrea Maurizio Cabibbe, Ivica Čabraja, Lucy Catteau, Emil Ceban, Olga Cerneţchi, Elena Chițan, Nelly Ciobanu, Osman Sezer Cirit, Valeriu Crudu, Raquel Duarte, Fusun Oner Eyuboglu, Federico Fama, Margaret M. Fitzgibbon, Agnes Gebhard, Evelina I. Gherghelegiu, Lorenzo Guglielmetti, Elmira Gurbanova, Sophia Hatzianastasiou, Eduard Kabasakalyan Published: 2026 On 8 and 9 June 2026, the 1st Conference on Antimicrobial Stewardship in Tuberculosis convened in Chişinău, Republic of Moldova, bringing together more than 60 experts from across the WHO European Region. The conference adopted the following call for action. We express our deep concern over the burden of drug-resistant tuberculosis and its central role in the global antimicrobial resistance crisis. Despite remarkable advances in medicine and public health, tuberculosis remains the leading infectious cause of death worldwide from a single pathogen.1 Treatment outcomes for drug-resistant tuberculosis remain substantially worse than for drug-susceptible disease, and treatment success rates for extensively drug-resistant tuberculosis approach levels last seen in the pre-antibiotic era.2 The WHO European Region, which bears a disproportionate share of this burden, has both a responsibility and an opportunity to lead global stewardship efforts. Major advances have transformed the treatment of drug-resistant tuberculosis. Long, burdensome, and often toxic regimens have increasingly been replaced by shorter, all-oral regimens, offering renewed hope. These advances, however, remain fragile. The emergence of resistance to bedaquiline, a cornerstone of current multidrug-resistant tuberculosis treatment, poses a serious threat to recent therapeutic progress.3 As additional anti-tuberculosis drugs are approved and introduced in the coming years, their long-term effectiveness will depend critically on how they are used from the outset. Therapeutic innovation alone will not be sufficient. Preserving the effectiveness of tuberculosis treatment requires that every new advance be matched by antimicrobial stewardship. Antimicrobial stewardship in tuberculosis is not optional–it is an essential component of quality care, safeguarding both individual treatment outcomes and the effectiveness of life-saving drugs for future generations. Without decisive action, recent therapeutic gains may prove short-lived, particularly in the communities and countries that already bear the heaviest burden. The International Clinical Standards for Antimicrobial Stewardship in Tuberculosis Care provide a framework for action.4 We call upon governments, international organizations, healthcare institutions, researchers, civil society, and healthcare professionals to embed antimicrobial stewardship as a pillar of tuberculosis care (Panel 1).Panel 1Priority actions to advance antimicrobial stewardship in tuberculosis care.We call for:•Governance, integration, and sustainable financing: Tuberculosis should be fully integrated into antimicrobial resistance action plans and stewardship frameworks at global, regional, and national levels. Sustainable financing must support stewardship activities, uninterrupted access to quality-assured anti-tuberculosis medicines, diagnostic capacity, surveillance systems, and resilient health infrastructure.•Education, capacity building, and expert consultation: Healthcare professionals, policymakers, and affected communities should receive continuous education on tuberculosis, antimicrobial resistance, and stewardship principles. Regional and national expert consultation services should be strengthened to support evidence-based clinical decision-making in complex and drug-resistant tuberculosis cases.•Surveillance, digital health, and regional collaboration: Robust surveillance systems and digital health tools should monitor drug resistance patterns, treatment adherence, and outcomes. Cross-border data sharing and regional collaboration should support coordinated stewardship efforts and rapid responses to emerging resistance.•Prevention of tuberculosis and drug resistance: Infection prevention and control, early diagnosis, and preventive treatment should reduce transmission and disease progression. Antimicrobial stewardship principles should be applied throughout the continuum of care to prevent the emergence and amplification of drug resistance.•Universal access to timely and comprehensive drug susceptibility testing: All people with tuberculosis should have rapid, equitable access to high-quality drug susceptibility testing, including molecular, sequencing-based, and emerging diagnostic approaches, to guide individualized and evidence-based treatment decisions.•Patient-centred care, treatment adherence, and stewardship in practice: People with tuberculosis should receive care prioritizing treatment effectiveness, safety, and resistance prevention. Structured adherence support, systematic monitoring, and comprehensive evaluation of suboptimal response or treatment failure should be integral to tuberculosis care. Priority actions to advance antimicrobial stewardship in tuberculosis care. We call for:•Governance, integration, and sustainable financing: Tuberculosis should be fully integrated into antimicrobial resistance action plans and stewardship frameworks at global, regional, and national levels. Sustainable financing must support stewardship activities, uninterrupted access to quality-assured anti-tuberculosis medicines, diagnostic capacity, surveillance systems, and resilient health infrastructure.•Education, capacity building, and expert consultation: Healthcare professionals, policymakers, and affected communities should receive continuous education on tuberculosis, antimicrobial resistance, and stewardship principles. Regional and national expert consultation services should be strengthened to support evidence-based clinical decision-making in complex and drug-resistant tuberculosis cases.•Surveillance, digital health, and regional collaboration: Robust surveillance systems and digital health tools should monitor drug resistance patterns, treatment adherence, and outcomes. Cross-border data sharing and regional collaboration should support coordinated stewardship efforts and rapid responses to emerging resistance.•Prevention of tuberculosis and drug resistance: Infection prevention and control, early diagnosis, and preventive treatment should reduce transmission and disease progression. Antimicrobial stewardship principles should be applied throughout the continuum of care to prevent the emergence and amplification of drug resistance.•Universal access to timely and comprehensive drug susceptibility testing: All people with tuberculosis should have rapid, equitable access to high-quality drug susceptibility testing, including molecular, sequencing-based, and emerging diagnostic approaches, to guide individualized and evidence-based treatment decisions.•Patient-centred care, treatment adherence, and stewardship in practice: People with tuberculosis should receive care prioritizing treatment effectiveness, safety, and resistance prevention. Structured adherence support, systematic monitoring, and comprehensive evaluation of suboptimal response or treatment failure should be integral to tuberculosis care. •Governance, integration, and sustainable financing: Tuberculosis should be fully integrated into antimicrobial resistance action plans and stewardship frameworks at global, regional, and national levels. Sustainable financing must support stewardship activities, uninterrupted access to quality-assured anti-tuberculosis medicines, diagnostic capacity, surveillance systems, and resilient health infrastructure. Governance, integration, and sustainable financing: Tuberculosis should be fully integrated into antimicrobial resistance action plans and stewardship frameworks at global, regional, and national levels. Sustainable financing must support stewardship activities, uninterrupted access to quality-assured anti-tuberculosis medicines, diagnostic capacity, surveillance systems, and resilient health infrastructure. •Education, capacity building, and expert consultation: Healthcare professionals, policymakers, and affected communities should receive continuous education on tuberculosis, antimicrobial resistance, and stewardship principles. Regional and national expert consultation services should be strengthened to support evidence-based clinical decision-making in complex and drug-resistant tuberculosis cases. Education, capacity building, and expert consultation: Healthcare professionals, policymakers, and affected communities should receive continuous education on tuberculosis, antimicrobial resistance, and stewardship principles. Regional and national expert consultation services should be strengthened to support evidence-based clinical decision-making in complex and drug-resistant tuberculosis cases. •Surveillance, digital health, and regional collaboration: Robust surveillance systems and digital health tools should monitor drug resistance patterns, treatment adherence, and outcomes. Cross-border data sharing and regional collaboration should support coordinated stewardship efforts and rapid responses to emerging resistance. Surveillance, digital health, and regional collaboration: Robust surveillance systems and digital health tools should monitor drug resistance patterns, treatment adherence, and outcomes. Cross-border data sharing and regional collaboration should support coordinated stewardship efforts and rapid responses to emerging resistance. •Prevention of tuberculosis and drug resistance: Infection prevention and control, early diagnosis, and preventive treatment should reduce transmission and disease progression. Antimicrobial stewardship principles should be applied throughout the continuum of care to prevent the emergence and amplification of drug resistance. Prevention of tuberculosis and drug resistance: Infection prevention and control, early diagnosis, and preventive treatment should reduce transmission and disease progression. Antimicrobial stewardship principles should be applied throughout the continuum of care to prevent the emergence and amplification of drug resistance. •Universal access to timely and comprehensive drug susceptibility testing: All people with tuberculosis should have rapid, equitable access to high-quality drug susceptibility testing, including molecular, sequencing-based, and emerging diagnostic approaches, to guide individualized and evidence-based treatment decisions. Universal access to timely and comprehensive drug susceptibility testing: All people with tuberculosis should have rapid, equitable access to high-quality drug susceptibility testing, including molecular, sequencing-based, and emerging diagnostic approaches, to guide individualized and evidence-based treatment decisions. •Patient-centred care, treatment adherence, and stewardship in practice: People with tuberculosis should receive care prioritizing treatment effectiveness, safety, and resistance prevention. Structured adherence support, systematic monitoring, and comprehensive evaluation of suboptimal response or treatment failure should be integral to tuberculosis care. Patient-centred care, treatment adherence, and stewardship in practice: People with tuberculosis should receive care prioritizing treatment effectiveness, safety, and resistance prevention. Structured adherence support, systematic monitoring, and comprehensive evaluation of suboptimal response or treatment failure should be integral to tuberculosis care. Beyond this call, conference participants committed themselves to a set of concrete actions to advance antimicrobial stewardship in tuberculosis care (Panel 2).Panel 2Commitments to advance antimicrobial stewardship in tuberculosis care.We commit ourselves:•to advancing antimicrobial stewardship as a core component of tuberculosis prevention, care, and control;•to promoting rational, evidence-based, and patient-centred tuberculosis treatment;•to fostering collaboration across disciplines, institutions, sectors, and countries;•to strengthening education, training, and research;•to advocating for equitable access to diagnostics and treatment; and•to safeguarding the effectiveness of anti-tuberculosis medicines for future generations. Commitments to advance antimicrobial stewardship in tuberculosis care. We commit ourselves:•to advancing antimicrobial stewardship as a core component of tuberculosis prevention, care, and control;•to promoting rational, evidence-based, and patient-centred tuberculosis treatment;•to fostering collaboration across disciplines, institutions, sectors, and countries;•to strengthening education, training, and research;•to advocating for equitable access to diagnostics and treatment; and•to safeguarding the effectiveness of anti-tuberculosis medicines for future generations. •to advancing antimicrobial stewardship as a core component of tuberculosis prevention, care, and control; to advancing antimicrobial stewardship as a core component of tuberculosis prevention, care, and control; •to promoting rational, evidence-based, and patient-centred tuberculosis treatment; to promoting rational, evidence-based, and patient-centred tuberculosis treatment; •to fostering collaboration across disciplines, institutions, sectors, and countries; to fostering collaboration across disciplines, institutions, sectors, and countries; •to strengthening education, training, and research; to strengthening education, training, and research; •to advocating for equitable access to diagnostics and treatment; and to advocating for equitable access to diagnostics and treatment; and •to safeguarding the effectiveness of anti-tuberculosis medicines for future generations. to safeguarding the effectiveness of anti-tuberculosis medicines for future generations. The fight against tuberculosis and antimicrobial resistance requires collective responsibility, collaboration, and sustained political will. Strengthening antimicrobial stewardship in tuberculosis care is essential to achieving the goals of the WHO End Tuberculosis Strategy and the global response to antimicrobial resistance.5 Failure to act risks reversing decades of progress and jeopardizing the effectiveness of life-saving anti-tuberculosis medicines for future generations. Contributors All authors contributed to the conceptualisation of the manuscript, interpretation of the evidence, drafting and critical revision of the text, and approved the final version for submission. Members of the AMS in TB study group contributed to the discussions at the conference that shaped this Call to Action and reviewed the final manuscript. Declaration of interests C.L. is supported by the German Center for Infection Research (DZIF). D.C. is supported by the German Center for Infection Research (DZIF). Outside the submitted work, C.L. has received consulting fees from Insmed and bioMérieux, and honoraria for lectures/speakers bureaus from Insmed, Gilead, AstraZeneca, GSK, and Medupdate (Europe); he is also a member of the WHO Guideline Development Group for tuberculosis. D.A.O. reports reimbursement of conference fees and travel for attending ESCMID Global 2024 to 26 in her role as speaker or chair of sessions on antimicrobial stewardship. T.T.B., A.Y. and I.P. declare no competing interests related to the present work.